Floatz logo

Eloxatin

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

Genzada Pharmaceuticals USA, Inc.Phase 1Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Inno-206
Falo, Louis, MD
Phase 4BBB
Romidepsin
Walter Hanel
Phase 2BBB

View all 50 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →